tetano
Editor, Senior Moderator
EJHaem
. 2023 May 10;4(3):745-750.
doi: 10.1002/jha2.697. eCollection 2023 Aug. SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731
Caitlin W Elgarten[SUP] 1 [/SUP], John A Kairalla[SUP] 2 [/SUP], Joel C Thompson[SUP] 3 [/SUP], Tamara P Miller[SUP] 4 [/SUP], Cindy Wang[SUP] 2 [/SUP], Susan Conway[SUP] 2 [/SUP], Mignon L Loh[SUP] 5 [/SUP], Elizabeth A Raetz[SUP] 6 [/SUP], Sumit Gupta[SUP] 7 [/SUP], Rachel E Rau[SUP] 8 [/SUP], Anne Angiolillo[SUP] 9 [/SUP], Karen R Rabin[SUP] 8 [/SUP], Sarah Alexander[SUP] 7 [/SUP]
Affiliations
Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).
Keywords: B‐ALL; SARS‐CoV‐2; pediatrics.
. 2023 May 10;4(3):745-750.
doi: 10.1002/jha2.697. eCollection 2023 Aug. SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731
Caitlin W Elgarten[SUP] 1 [/SUP], John A Kairalla[SUP] 2 [/SUP], Joel C Thompson[SUP] 3 [/SUP], Tamara P Miller[SUP] 4 [/SUP], Cindy Wang[SUP] 2 [/SUP], Susan Conway[SUP] 2 [/SUP], Mignon L Loh[SUP] 5 [/SUP], Elizabeth A Raetz[SUP] 6 [/SUP], Sumit Gupta[SUP] 7 [/SUP], Rachel E Rau[SUP] 8 [/SUP], Anne Angiolillo[SUP] 9 [/SUP], Karen R Rabin[SUP] 8 [/SUP], Sarah Alexander[SUP] 7 [/SUP]
Affiliations
- PMID: 37601850
- PMCID: PMC10435702
- DOI: 10.1002/jha2.697
Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).
Keywords: B‐ALL; SARS‐CoV‐2; pediatrics.